Interscope

Executive Summary

Interscope is a privately held medical device company based in Plymouth Meeting, Pennsylvania, focused on advancing endoscopic procedures through its proprietary EndoRotor® system. Founded in 2003, the company has developed a next-generation interventional device designed for tissue resection and debridement, specifically addressing challenges in gastroenterology such as endoscopic necrosectomy and removal of residual or scarred tissue after endoscopic mucosal resection (EMR). The EndoRotor utilizes a novel rotating catheter technology that enables precise and controlled tissue removal, offering potential advantages over existing methods including reduced procedure time and improved safety. By targeting unmet needs in therapeutic endoscopy, Interscope positions itself within a growing market driven by the increasing adoption of minimally invasive gastrointestinal procedures. Despite its innovative technology, Interscope operates as a private company with limited publicly available financial or operational data, and its commercial traction remains unclear. The company's success hinges on regulatory clearances, clinical evidence generation, and adoption by gastroenterologists. The EndoRotor has received FDA clearance for certain indications, but broader market penetration will require additional clinical data and competitive differentiation. Key risks include competition from established endoscopic tools and the need for robust reimbursement coverage. With a focused product portfolio and a niche application, Interscope has potential but faces hurdles typical of early-stage medical device companies. The conviction score reflects a balanced view of its technological promise and uncertainties in commercialization.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance for expanded indication in necrosectomy70% success
• Q4 2026Publication of pivotal clinical trial results for EndoRotor in complex polypectomy65% success
• Q3 2026Strategic partnership or distribution agreement for U.S. commercialization50% success